Lyerly D M, Kreger A S
Infect Immun. 1983 Apr;40(1):113-9. doi: 10.1128/iai.40.1.113-119.1983.
The results of studies to evaluate the possible importance of serratia proteases in the development of experimental Serratia marcescens pneumonia revealed the following. (i) Administration of a highly purified serratia protease to the lungs of guinea pigs and mice resulted in extensive pulmonary edema and hemorrhage similar to that observed in animals having an experimentally induced, acute serratia pneumonia. (ii) Guinea pigs subcutaneously vaccinated with the protease developed low levels of antiprotease antibodies and were partially protected against serratia pneumonia, as demonstrated by a significant increase in survival time. Mice intranasally vaccinated with the protease also developed antiprotease antibodies and were protected against serratia pneumonia, as demonstrated by a significant increase in survival time and an increase in the number of survivors. (iii) Serratia protease was detected in lung tissue extracts prepared from the lungs of guinea pigs dying of serratia pneumonia. Our findings support the idea that serratia protease(s) is involved in the pathogenesis of experimental serratia pneumonia.
(i) 给豚鼠和小鼠肺部注射高度纯化的粘质沙雷氏菌蛋白酶，会导致广泛的肺水肿和出血，这与在实验性诱导的急性粘质沙雷氏菌肺炎动物中观察到的情况相似。(ii) 皮下接种该蛋白酶的豚鼠产生了低水平的抗蛋白酶抗体，并对粘质沙雷氏菌肺炎有部分保护作用，这表现为存活时间显著延长。经鼻接种该蛋白酶的小鼠也产生了抗蛋白酶抗体，并对粘质沙雷氏菌肺炎有保护作用，这表现为存活时间显著延长和存活小鼠数量增加。(iii) 在死于粘质沙雷氏菌肺炎的豚鼠肺部制备的肺组织提取物中检测到了粘质沙雷氏菌蛋白酶。我们的研究结果支持这样一种观点，即粘质沙雷氏菌蛋白酶参与了实验性粘质沙雷氏菌肺炎的发病机制。
